- Seasonal influenza activity remains low nationally.
- In clinical laboratories, 0.9% of specimens tested positive for influenza.
- In public health laboratories, there was a predominance of influenza A (H3N2) viruses.
- Outpatient respiratory illness visits accounted for 2.4% of patient visits, below the national baseline of 2.5%.
- Four jurisdictions experienced moderate ILI activity, while three jurisdictions experienced high activity.
- Influenza-associated hospitalizations have decreased compared to the previous week.
- Pneumonia, influenza, and COVID-19 (PIC) mortality remained above the epidemic threshold.
- Eight influenza-associated pediatric deaths were reported, bringing the total to 125 for the season.
- The majority of tested influenza viruses were susceptible to antiviral medications.
- The recommended vaccine for the 2023-2024 influenza season includes updates to the A(H1N1)pdm09 component.